Effects of lysed Enterococcus faecalis FK‐23 on allergen‐induced serum antibody responses and active cutaneous anaphylaxis in mice
- 12 November 2004
- journal article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 34 (11) , 1784-1788
- https://doi.org/10.1111/j.1365-2222.2004.02092.x
Abstract
Background Our previous studies have presented evidence that lysed Enterococcus faecalis FK‐23 (LFK), a lysozyme and heat‐treated probiotic product, can inhibit allergen‐induced local accumulation of eosinophils in mice. Objective The purpose of this experimental study was to evaluate the influence of orally administrated LFK on the host immune responses. Methods BALB/c mice were sensitized subcutaneously, and challenged intraperitoneally by cedar pollen allergen. Blood and spleen samples were collected after oral administration of LFK 60 mg/day for 21 days. The serum levels of total and allergen‐specific IgE and IgG2a antibodies and the production of IL‐4, IL‐5 and IFN‐γ generated by allergen‐stimulated cultured splenocytes were determined. Additionally, the effect of LFK on active cutaneous anaphylaxis (ACA) induced by ovalbumin (OVA) challenge in mice was measured after 28 days LFK treatment. Results No significant differences in serum immunoglobulin levels, as well as in cytokine production of splenocytes were observed between LFK‐treated and control mice (P>0.05). There was, however, an increasing tendency of allergen‐specific IgG2a level in mice after LFK treatment for 21 days compared with controls (P=0.060). Furthermore, the serum ratio of specific IgE to IgG2a was found to be significantly decreased in the LFK group (P=0.005). In addition, a significant inhibition of OVA‐induced ACA reaction was observed in mice that had been fed for 28 days with LFK compared with control mice (P=0.008). Conclusion These results suggest that LFK shows an anti‐inflammatory effect, which may be part of the mechanism for protection against IgE‐mediated allergy.Keywords
This publication has 26 references indexed in Scilit:
- Allergic symptoms and microflora in schoolchildrenJournal of Adolescent Health, 2004
- Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trialThe Lancet, 2003
- Role of intestinal flora in the development of allergyCurrent Opinion in Allergy and Clinical Immunology, 2003
- Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infantJournal of Allergy and Clinical Immunology, 2002
- Allergy development and the intestinal microflora during the first year of lifeJournal of Allergy and Clinical Immunology, 2001
- Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trialThe Lancet, 2001
- Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developingJournal of Allergy and Clinical Immunology, 2001
- Microflora‐associated characteristics in faeces from allergic and nonallergic infantsClinical and Experimental Allergy, 2000
- Probiotics in the management of atopic eczemaClinical and Experimental Allergy, 2000
- The intestinal microflora in allergic Estonian and Swedish 2‐year‐old childrenClinical and Experimental Allergy, 1999